TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Brief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer


Options:
A: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: zoledronic acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: denosumab | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): zoledronic acid | Intervention Type: BIOLOGICAL; Name: denosumab; Assigned to Arm(s): denosumab
B: Arm Label: Thalidomide + Bisphosphonate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate, Drug: Thalidomide, Drug: Zometa | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Thalidomide + Bisphosphonate
C: Intervention Type: DRUG; Name: pamidronate; Assigned to Arm(s): N/A
D: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short and Long-term Effects of Exercise and Education as Self-management in Women With Fibromyalgia
Brief Summary: The overall objective of this work is to improve treatment outcomes for persons with fibromyalgia by optimizing the approach to self-management. The purpose of this research project is to evaluate and compare, in a randomized, controlled trial involving 200 women, the short and long-term effectiveness of four approaches to fibromyalgia self-management for improving health and functional status, self-efficacy, and symptom severity. Additionally, we will also examine the effect of each intervention on health care usage. We will assess the following 16-week interventions:

* cardiovascular and flexibility exercise
* strength training, cardiovascular and flexibility exercise
* Arthritis Foundation's Fibromyalgia Self-Help course
* a combination of the Fibromyalgia Self-Help Course and strength training exercise interventions


Options:
A: Arm Label: A. High intensive exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Arm Label: B. Low-intensive exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active comparator: low intensive exercise | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): A. High intensive exercise | Intervention Type: BEHAVIORAL; Name: Active comparator: low intensive exercise; Assigned to Arm(s): B. Low-intensive exercise
B: Arm Label: Aerobic and flexibility exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic | Arm Label: Strength, aerobic, and flexibility; Type: EXPERIMENTAL; Interventions: Behavioral: Strength training | Arm Label: Fibromyalgia Self-Help Course; Type: EXPERIMENTAL; Interventions: Behavioral: FSHC | Arm Label: a Combination of ST and FSHC; Type: EXPERIMENTAL; Interventions: Behavioral: Combination | Intervention Type: BEHAVIORAL; Name: Aerobic; Assigned to Arm(s): Aerobic and flexibility exercise | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): Strength, aerobic, and flexibility | Intervention Type: BEHAVIORAL; Name: Combination; Assigned to Arm(s): a Combination of ST and FSHC | Intervention Type: BEHAVIORAL; Name: FSHC; Assigned to Arm(s): Fibromyalgia Self-Help Course
C: Arm Label: Dance Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dance | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: Other: Control Group | Intervention Type: BEHAVIORAL; Name: Dance; Assigned to Arm(s): Dance Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
D: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short and Long-term Effects of Exercise and Education as Self-management in Women With Fibromyalgia
Brief Summary: The overall objective of this work is to improve treatment outcomes for persons with fibromyalgia by optimizing the approach to self-management. The purpose of this research project is to evaluate and compare, in a randomized, controlled trial involving 200 women, the short and long-term effectiveness of four approaches to fibromyalgia self-management for improving health and functional status, self-efficacy, and symptom severity. Additionally, we will also examine the effect of each intervention on health care usage. We will assess the following 16-week interventions:

* cardiovascular and flexibility exercise
* strength training, cardiovascular and flexibility exercise
* Arthritis Foundation's Fibromyalgia Self-Help course
* a combination of the Fibromyalgia Self-Help Course and strength training exercise interventions


Options:
A: Arm Label: Tai Chi Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi Intervention | Arm Label: Control Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control Intervention | Intervention Type: BEHAVIORAL; Name: Tai Chi Intervention; Assigned to Arm(s): Tai Chi Intervention | Intervention Type: BEHAVIORAL; Name: Control Intervention; Assigned to Arm(s): Control Intervention
B: Intervention Type: BEHAVIORAL; Name: walking program, resistance muscular exercise; Assigned to Arm(s): N/A
C: Arm Label: Aerobic and flexibility exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic | Arm Label: Strength, aerobic, and flexibility; Type: EXPERIMENTAL; Interventions: Behavioral: Strength training | Arm Label: Fibromyalgia Self-Help Course; Type: EXPERIMENTAL; Interventions: Behavioral: FSHC | Arm Label: a Combination of ST and FSHC; Type: EXPERIMENTAL; Interventions: Behavioral: Combination | Intervention Type: BEHAVIORAL; Name: Aerobic; Assigned to Arm(s): Aerobic and flexibility exercise | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): Strength, aerobic, and flexibility | Intervention Type: BEHAVIORAL; Name: Combination; Assigned to Arm(s): a Combination of ST and FSHC | Intervention Type: BEHAVIORAL; Name: FSHC; Assigned to Arm(s): Fibromyalgia Self-Help Course
D: Arm Label: A. High intensive exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Arm Label: B. Low-intensive exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active comparator: low intensive exercise | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): A. High intensive exercise | Intervention Type: BEHAVIORAL; Name: Active comparator: low intensive exercise; Assigned to Arm(s): B. Low-intensive exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
Brief Summary: The purpose of the study was to assess the efficacy and safety of NGX-4010 applied for 30 or 60 minutes for the treatment of painful HIV-associated neuropathy.


Options:
A: Arm Label: capsaicin patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: capsaicin patch (qutenza) | Arm Label: placebo patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: capsaicin patch (qutenza); Assigned to Arm(s): capsaicin patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo patch
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
C: Arm Label: NGX-4010, 60 minutes; Type: EXPERIMENTAL; Interventions: Drug: NGX-4010, 8% capsaicin patch | Arm Label: NGX-4010, 30 minutes; Type: EXPERIMENTAL; Interventions: Drug: NGX-4010, 8% capsaicin patch | Arm Label: 0.04% conc. capsaicin patch, 60 min.; Type: OTHER; Interventions: Drug: 0.04% capsaicin patch | Arm Label: 0.04% conc. capsaicin patch, 30 min.; Type: OTHER; Interventions: Drug: 0.04% capsaicin patch | Intervention Type: DRUG; Name: NGX-4010, 8% capsaicin patch; Assigned to Arm(s): NGX-4010, 60 minutes | Intervention Type: DRUG; Name: 0.04% capsaicin patch; Assigned to Arm(s): 0.04% conc. capsaicin patch, 60 min. | Intervention Type: DRUG; Name: NGX-4010, 8% capsaicin patch; Assigned to Arm(s): NGX-4010, 30 minutes | Intervention Type: DRUG; Name: 0.04% capsaicin patch; Assigned to Arm(s): 0.04% conc. capsaicin patch, 30 min.
D: Arm Label: Capsaicin 8%; Type: EXPERIMENTAL; Interventions: Drug: Capsaicin 8% | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Capsaicin 8%; Assigned to Arm(s): Capsaicin 8% | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Patient-Spouse Intervention for Self-Managing High Cholesterol
Brief Summary: We examined the effect of a patient-spouse intervention to lower LDL-C by increasing patient treatment adherence. A randomized controlled trial compared a one-year, telephone-based patient-spouse intervention to usual care. The primary outcome was LDL-C measured three times (baseline, 6 months, 11 months); secondary outcomes were adherence to medication, diet, and exercise, also assessed at baseline, 6 months, and 11 months.


Options:
A: Arm Label: lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: lifestyle intervention | Intervention Type: OTHER; Name: lifestyle intervention; Assigned to Arm(s): lifestyle intervention
B: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program (SM) | Arm Label: Care Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Care management program (CM) | Intervention Type: BEHAVIORAL; Name: Self-management program (SM); Assigned to Arm(s): Self-Management Program | Intervention Type: BEHAVIORAL; Name: Care management program (CM); Assigned to Arm(s): Care Management Program
D: Arm Label: Spouse-assisted intervention; Type: EXPERIMENTAL; Interventions: Behavioral: spouse-assisted intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: spouse-assisted intervention; Assigned to Arm(s): Spouse-assisted intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen
Brief Summary: To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.


Options:
A: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm
C: Arm Label: Melanoma - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: RCC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: mCRPC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: NSCLC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: CRC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): Melanoma - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): RCC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): mCRPC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): NSCLC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): CRC - BMS-936558 (MDX-1106)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PF-3512676 + Erlotinib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erlotinib | Intervention Type: DRUG; Name: PF-3512676 + Erlotinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.
Brief Summary: This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease


Options:
A: Arm Label: Methylphenidate 0.4 mg/kg TID followed by placebo TID; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate | Arm Label: Placebo TID followed by methylphenidate 0.4 mg/kg TID; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): Methylphenidate 0.4 mg/kg TID followed by placebo TID, Placebo TID followed by methylphenidate 0.4 mg/kg TID
B: Arm Label: 1mg rasagiline; Type: EXPERIMENTAL; Interventions: Drug: Rasagiline Mesylate | Arm Label: 2mg rasagiline; Type: EXPERIMENTAL; Interventions: Drug: Rasagiline Mesylate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rasagiline Mesylate; Assigned to Arm(s): 1mg rasagiline | Intervention Type: DRUG; Name: Rasagiline Mesylate; Assigned to Arm(s): 2mg rasagiline | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pardoprunox | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pardoprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: Early Pramipexole; Type: EXPERIMENTAL; Interventions: Drug: pramipexole | Arm Label: Delayed Pramipexole; Type: EXPERIMENTAL; Interventions: Drug: pramipexole | Intervention Type: DRUG; Name: pramipexole; Assigned to Arm(s): Delayed Pramipexole, Early Pramipexole

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Porcine-Derived Small Intestine Submucosa Graft-Augmented Rectocele Repair-A Randomized Trial
Brief Summary: The purpose of this study is to determine whether adding a graft during a rectocele repair will improve the success rate of the repair.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Avaulta (surgical procedure using a mesh implant) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional surgery (anterior repair) | Intervention Type: PROCEDURE; Name: Avaulta (surgical procedure using a mesh implant); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional surgery (anterior repair); Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Control | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Graft augmented posterior repair | Intervention Type: PROCEDURE; Name: Graft augmented posterior repair; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): 1
C: Intervention Type: DEVICE; Name: Low-weight prolypropylene mesh; Assigned to Arm(s): N/A
D: Arm Label: Mesh surgery; Type: EXPERIMENTAL; Interventions: Device: Tensionfree vaginal mesh kit (Prolift) | Arm Label: Conventional vaginal surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: classic vaginal prolapse surgery (fascia plication) | Intervention Type: DEVICE; Name: Tensionfree vaginal mesh kit (Prolift); Assigned to Arm(s): Mesh surgery | Intervention Type: PROCEDURE; Name: classic vaginal prolapse surgery (fascia plication); Assigned to Arm(s): Conventional vaginal surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study of the Effect of NeoRecormon on Reduction of Cardiovascular Risk in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy.
Brief Summary: This study will evaluate whether anemia prevention with NeoRecormon has an additional impact on reducing cardiovascular risk over conventional anemia treatment in patients mostly with stage IV chronic kidney disease and renal anemia. The anticipated time on study treatment is 2+ years and the target sample size is 500+ individuals.


Options:
A: Arm Label: Group 1 (Early Epoetin Beta); Type: EXPERIMENTAL; Interventions: Drug: Epoetin beta | Arm Label: Group 2 (No/Late Epoetin Beta); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin beta | Intervention Type: DRUG; Name: Epoetin beta; Assigned to Arm(s): Group 1 (Early Epoetin Beta), Group 2 (No/Late Epoetin Beta)
B: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
C: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study of the Effect of NeoRecormon on Reduction of Cardiovascular Risk in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy.
Brief Summary: This study will evaluate whether anemia prevention with NeoRecormon has an additional impact on reducing cardiovascular risk over conventional anemia treatment in patients mostly with stage IV chronic kidney disease and renal anemia. The anticipated time on study treatment is 2+ years and the target sample size is 500+ individuals.


Options:
A: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
B: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
C: Arm Label: Cohort A (0.4/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort B (0.4/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort C (0.4/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort D (0.8/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort E (0.8/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort F (0.8/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort G (1.2/150, 1x/ Week); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort H (1.2/150, 1x/ 3 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort I (1.2/150, 1x/ 4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): Cohort A (0.4/150, 1x/ Week), Cohort B (0.4/150, 1x/ 3 Weeks), Cohort C (0.4/150, 1x/ 4 Weeks), Cohort D (0.8/150, 1x/ Week), Cohort E (0.8/150, 1x/ 3 Weeks), Cohort F (0.8/150, 1x/ 4 Weeks), Cohort G (1.2/150, 1x/ Week), Cohort H (1.2/150, 1x/ 3 Weeks), Cohort I (1.2/150, 1x/ 4 Weeks)
D: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B